ArticleThe Journal of clinical endocrinology and metabolism2026
Increasing incidence and prevalence of biochemically confirmed primary hyperparathyroidism in Stockholm, 2006-2020.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Increasing incidence and prevalence of biochemically confirmed primary hyperparathyroidism in Stockholm, 2006-2020.The Journal of clinical endocrinology and metabolism · 2026Article
- Short-term biochemical outcomes after microwave ablation versus parathyroidectomy for primary hyperparathyroidism: an IPTW analysis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
contextPrimary hyperparathyroidism (PHPT) prevalence appears to be rising, but substantial underdiagnosis persists. Accurate epidemiological data are needed, requiring population-based studies using strict biochemical criteria.
objectiveTo determine incidence and prevalence of biochemically confirmed PHPT in Stockholm and characterize clinical recognition and surgical management.
methodsThis is a population-based healthcare cohort study using prespecified biochemical diagnostic algorithms in the Stockholm Region, Sweden, 2006-2020, using the Stockholm CREAtinine Measurements database which covers two-thirds of the adult population, including ≥90% of individuals ≥65 years. Adults aged ≥20 years with paired calcium and parathyroid hormone (PTH) measurements meeting biochemical criteria for PHPT were included. Individuals with estimated glomerular filtration rate ≤30 mL/min/1.73 m2, secondary hyperparathyroidism, or prior parathyroid surgery were excluded. Main outcome measures were the annual incidence rate and point prevalence of biochemically confirmed PHPT.
resultsAmong 176 780 individuals contributing 578 227 PTH measurements, 10 190 patients fulfilling biochemical PHPT criteria were identified. Age- and sex-adjusted incidence rate increased from 2.81 (95% CI, 2.55-3.09) to 4.28 (95% CI, 3.98-4.59) per 10 000 person-years between 2009 and 2020, with the steepest increase among women aged ≥70 years. Prevalence increased from 0.35 to 4.76 per 1000 individuals. Median ionized calcium was 1.39 mmol/L. Clinical diagnosis of PHPT was documented in 5346 (52%) patients, of which 2800 (52%) underwent parathyroidectomy, with surgery rates stabilizing after 2013 at 4% to 5% annually.
conclusionUsing a large healthcare database, we observed substantially increasing PHPT incidence and prevalence, predominantly in older individuals. Only 52% received clinical diagnosis, underscoring the need for studies evaluating the long-term clinical burden of undiagnosed PHPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.